ArticleBMC cancer2025
The feasibility and cost-effectiveness of implementing mobile low-dose computed tomography with an AI-based diagnostic system in underserved populations.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Cost-Effectiveness and Budget Impact of Lung Cancer Screening: A Systematic Review.PharmacoEconomics · 2026Pooled it
- Cost-effectiveness of lung cancer screening: insights from risk stratification, guidelines, and emerging technologies-a systematic review.NPJ primary care respiratory medicine · 2026Pooled it
- Effectiveness and implementation challenges of mobile low-dose computed tomography units for early lung cancer detection: a systematic review.Frontiers in public health · 2026Pooled it
- Economic evaluation of AI-assisted technologies in healthcare: A systematic review.Journal of food and drug analysis · 2025Pooled it
- Assessing the Value for Money of AI-Assisted Technologies for Older Adults: Scoping Review of Economic Evaluations.Journal of medical Internet research · 2026Article
- [Detection Status and Cost Analysis of Community Pulmonary Nodule Screening with Mobile LDCT Combined with AI].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- Human-AI Collaboration in Healthcare: A Scoping Review.NPJ digital medicine · 2026Article
- Applying artificial intelligence to ensure high quality and equitable lung cancer screening.Translational lung cancer research · 2026Review
- Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes.Journal of cancer research and clinical oncology · 2026Review
- A new era of precision diagnosis and treatment for lung cancer: artificial intelligence-driven multimodal data integration and clinical applications.Cell death & disease · 2026Review
- Review
- Artificial Intelligence in Lung Cancer: A Narrative Review of Recent Advances in Diagnosis, Biomarker Discovery, and Drug Development.Pharmaceutics · 2026Review
- The impact of digital economy on primary healthcare institution efficiency: evidence from China based on spatial effect analysis.BMC primary care · 2026Article
- Multimodal diagnostic imaging for early mitral valve disease: integration of current and emerging modalities-a narrative review.Cardiovascular diagnosis and therapy · 2025Review
- Decentralizing Pulmonary Screening for China's Aging Population: From Hospitals to Communities.Aging and disease · 2025Article
- Transforming Cancer Care: A Narrative Review on Leveraging Artificial Intelligence to Advance Immunotherapy in Underserved Communities.Journal of clinical medicine · 2025Review
- Using Convoluted Neural Networks in Diagnosing Lung Cancer on Computed Tomography Scans.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLow-dose computed tomography (LDCT) significantly increases early detection rates of lung cancer and reduces lung cancer-related mortality by 20%. However, many significant screening barriers remain. This study conduct an initial feasibility and cost-effectiveness analysis of a community-based program that used a mobile low-dose computed tomography (LDCT) scan unit and discuss the operational challenges faced during its implementation.
methodsThis study was conducted in rural areas in Fujian Province, China from July 2022 to August 2022. Individuals aged 40 years and above who had not previously undergone LDCT and who were socioeconomically marginalized were included. Participants received a LDCT program from a multidisciplinary research team. Physicians analyzed the images with the assistance of artificial intelligence "InferRead CT Lung Research" and completed structured reports on their impressions. The primary evaluation indicators for mobile LDCT screening effectiveness were the lung cancer detection rate and diagnosis rate, while the main evaluation indicators for cost-effective analysis were the cost-effective ratio and early detection cost index.
resultsA total of 10,159 individuals participated in this study. The detection rates of suspected lung cancer cases and confirmed cases were 1.06% (n = 108) and 0.7% (n = 71), respectively. The cost of lung cancer screening (LCS) was ¥1,203,504 (US$188,847.71), the average cost per screening was ¥118.47 (US$18.65), and the cost effective ratios for the detection of suspected lung cancer and confirmed lung cancer were ¥11,143.56 (US$1,753.29) and ¥16,950.76 (US$2,669.94), respectively. The early detection cost indices for suspected lung cancer were 0.09 and 0.13 for confirmed lung cancer, respectively.
conclusionThis LDCT with artificial intelligence model for LCS holds economic promise for reducing health disparities in underserved areas and promote larger populations in similar low-income country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.